Analysis: Is the Polynovo share price good value?

The Polynovo Ltd (ASX: PNV) share price jumped 8.1% higher last week but is the ASX biotech share a good value buy?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Polynovo Ltd (ASX: PNV) share price was a strong performer last week and closed the five days of trade 8.1% higher at $2.66 per share. At the time of writing on Monday, Polynovo shares had edged slightly lower to $2.64.

Shares in the Aussie biotech have consistently outperformed the S&P/ASX 200 Index (ASX: XJO) and continued to climb higher in 2020. So, how has this happened and is it sustainable?

What has happened in the last 12 months?

It's been a big start to the year for Polynovo and its investors. Despite slumping in the recent bear market, the Polynovo share price has surged back to life.

Strong sales have been a key factor behind the biotech company's share price growth. Polynovo's CSIRO-developed NovoSorb BTM product continues to kick goals in Australia and abroad.

In April, Polynovo announced the first use of its NovoSorb BTM product in Canada through Health Canada's Special Access Program (SAP). The company is working towards regulatory approval in 2021 which could open up another huge addressable market.

The successful news follows record monthly sales in the United States and an upward trajectory which has propelled the Polynovo share price higher.

What about the company's financials?

Interestingly enough, the company's half-year results in February didn't go down well with investors. In fact, the Polynovo share price fell 20% on the back of the 26 February results release.

The company reported an 80% increase in yearly revenue to $10.2 million with a 129% increase in NovoSorb BTM sales to $8.6 million. In some good news for growth investors, NovoSorb BTM sales more than tripled in January 2020 compared to January 2019 figures.

However, Polynovo reported a net loss after tax of $2.4 million in February. In my opinion, that in itself isn't a worry, particularly for an R&D heavy growth company like Polynovo.

What is the outlook for the Polynovo share price?

Clearly, the coronavirus pandemic has thrown a spanner in the works for predicting what will happen in FY21.

Polynovo management did say that NovoSorb BTM sales for FY20 should comfortably double FY19, but that was all pre-pandemic.

The company continues to invest heavily in R&D and sales are trending upward. I think there's really strong growth potential for the Polynovo share price in 2020 and beyond.

If the company can execute its plans in the lucrative hernia and breast augmentation and reconstruction industries, who knows just how high the Polynovo share price could climb.

Foolish takeaway

The Polynovo share price has been a consistent performer over the last 5 years. Of course, past performance isn't a reliable indicator of future performance.

However, it seems to me the company has a strong sales pipeline and clear room for growth in 2020. While Polynovo is a speculative buy and heavily dependent on future sales growth, the technical environment does look strong.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »